Marc Hedrick
Chief Executive Officer bij PLUS THERAPEUTICS, INC.
Vermogen: 370 $ op 31-03-2024
Profiel
Marc H.
Hedrick was the founder of StemSource, Inc. (founded in 2000), where he served as President, Chief Executive Officer & Director from 2001 to 2003.
He is currently the President, Chief Executive Officer & Director at Plus Therapeutics, Inc. since 2002 and a Director at Cytori Ltd.
He previously held the position of President, Chief Executive Officer & Director at Cytori Therapeutics, Inc. (JP).
From 2002 to 2004, he was the Chief Scientific Officer & Medical Director at MacroPore Biosurgery, Inc. He also served as Co-Director at UCLA Anderson School of Management and as an Associate Professor at the University of California, Los Angeles.
Dr. Hedrick holds a doctorate degree from The University of Texas Southwestern Medical Center (conferred in 1988) and an MBA from UCLA Anderson School of Management (conferred in 2005).
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
PLUS THERAPEUTICS, INC.
0.00% | 22-02-2024 | 170 ( 0.00% ) | 307 $ | 31-03-2024 |
| 25-07-2018 | 35 ( 3.73% ) | 63 $ | 31-03-2024 |
Actieve functies van Marc Hedrick
| Bedrijven | Functie | Begin |
|---|---|---|
| PLUS THERAPEUTICS, INC. | Chief Executive Officer | 02-04-2014 |
Eerdere bekende functies van Marc Hedrick
| Bedrijven | Functie | Einde |
|---|---|---|
| MacroPore Biosurgery, Inc. /Old/ | Chief Tech/Sci/R&D Officer | 01-01-2004 |
StemSource, Inc.
 StemSource, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Plus Therapeutics, Inc., StemSource, Inc. develops treatments for cancer. The private company is based in Thousand Oaks, CA. The company was founded by Adam J. Katz, Marc H. Hedrick. StemSource was acquired by MacroPore Biosurgery, Inc. on November 30, 2002 for $5.71 million. | Founder | 01-01-2003 |
| UCLA Anderson School of Management | Corporate Officer/Principal | - |
| University of California, Los Angeles | Corporate Officer/Principal | - |
Cytori Therapeutics, Inc. (JP)
 Cytori Therapeutics, Inc. (JP) BiotechnologyHealth Technology Cytori Therapeutics KK engages in the manufacture, import, export and sales of medical devices. The company was founded in 2002 and is headquartered in Tokyo, Japan. | Chief Executive Officer | - |
Opleiding van Marc Hedrick
| The University of Texas Southwestern Medical Center | Doctorate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PLUS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
| MacroPore Biosurgery, Inc. /Old/ | Health Technology |
StemSource, Inc.
StemSource, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Plus Therapeutics, Inc., StemSource, Inc. develops treatments for cancer. The private company is based in Thousand Oaks, CA. The company was founded by Adam J. Katz, Marc H. Hedrick. StemSource was acquired by MacroPore Biosurgery, Inc. on November 30, 2002 for $5.71 million. | Commercial Services |
Cytori Ltd.
 Cytori Ltd. Pharmaceuticals: OtherHealth Technology Cytori Ltd. develops biological products. The company was founded on February 7, 2014 and is headquartered in Deeside, the United Kingdom. | Health Technology |
Cytori Therapeutics, Inc. (JP)
Cytori Therapeutics, Inc. (JP) BiotechnologyHealth Technology Cytori Therapeutics KK engages in the manufacture, import, export and sales of medical devices. The company was founded in 2002 and is headquartered in Tokyo, Japan. | Health Technology |
